SKYSONA (elivaldogene autotemcel) 30000000 1/1 SUSPENSION

SKYSONA (elivaldogene autotemcel)

Active Ingredient:
elivaldogene autotemcel
Form:
SUSPENSION
Brand:
SKYSONA
Origin:
USA

Buy SKYSONA (elivaldogene autotemcel) elivaldogene autotemcel

SKYSONA (elivaldogene autotemcel) is an FDA-approved gene therapy for cerebral adrenoleukodystrophy (CALD), a rare inherited neurological disorder. It represents a breakthrough in cell and gene therapy, utilizing autologous hematopoietic stem cells modified ex vivo to treat this devastating condition. The drug was granted orphan drug designation and accelerated approval due to its potential to halt disease progression in eligible patients.

Strength

30000000 1/1

Pack Size

1 SUSPENSION in 1 BAG (73554-2111-1)

Manufacturer / TM Owner

Genetix Biotherapeutics Inc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Uses / Indications

  • SKYSONA is indicated for the treatment of cerebral adrenoleukodystrophy (CALD) in patients with early symptomatic disease. CALD is a rare, X-linked inherited metabolic disorder characterized by progressive neurological deterioration, demyelination, and adrenal insufficiency. The drug targets a specific patient population: males with CALD who have evidence of early cerebral involvement but retain sufficient neurological function. SKYSONA works through a gene therapy mechanism wherein the patient's own hematopoietic stem cells are harvested, transduced ex vivo with a lentiviral vector carrying the functional ABCD1 gene, and then reinfused intravenously. This approach aims to restore the deficient ABCD1 protein function, halt disease progression, and potentially improve neurological outcomes. The therapy addresses the underlying genetic defect rather than providing symptomatic relief, offering a potentially disease-modifying treatment option for this otherwise progressive and fatal condition.

Side Effects

  • Common adverse events associated with SKYSONA include myelosuppression, infections, and infusion-related reactions. Serious adverse events may include severe infections, graft failure, secondary malignancies, and neurological complications. Patients require intensive monitoring including complete blood counts, immunological assessments, and neurological evaluations. Hematologic monitoring is essential during the engraftment period. Long-term follow-up is necessary to assess efficacy, detect delayed adverse events, and monitor for potential genotoxicity. Infectious disease prophylaxis and supportive care measures are typically implemented during the treatment period.

Precautions & Warnings

  • SKYSONA is contraindicated in patients with active infections or severe immunodeficiency. Caution is warranted in patients with hepatic or renal impairment, as these may affect drug metabolism and clearance. The drug is not indicated for females or asymptomatic males. Pregnancy is a relative contraindication due to the nature of the therapy and potential risks. Pediatric use is limited to males with early symptomatic CALD; careful patient selection is critical. Patients must have adequate organ function and no contraindications to myeloablative conditioning. Pre-treatment assessment including genetic confirmation, neuroimaging, and functional status evaluation is mandatory. Informed consent regarding long-term follow-up requirements and potential risks is essential.

Avoid Interactions

  • SKYSONA has limited known direct drug-drug interactions as it is a cell-based gene therapy. However, concurrent use of immunosuppressive agents, chemotherapy, or other myelosuppressive medications may potentiate hematologic toxicity and should be carefully coordinated. Antimicrobial prophylaxis is often administered concurrently without significant interactions. Patients should avoid live vaccines during and after treatment due to immunosuppression. Coordination with conditioning regimens used prior to cell reinfusion is critical for optimal outcomes.

Frequently Asked Questions

SKYSONA is used to treat cerebral adrenoleukodystrophy (CALD), a rare inherited neurological disorder caused by mutations in the ABCD1 gene. It is specifically indicated for male patients with early symptomatic CALD who have evidence of early cerebral involvement. The therapy works by modifying the patient's own stem cells to restore the deficient ABCD1 protein function.

SKYSONA is administered intravenously as a one-time infusion of autologous hematopoietic stem cells that have been genetically modified ex vivo. Prior to infusion, patients typically undergo myeloablative conditioning to prepare the bone marrow for cell engraftment. The procedure is performed in a specialized medical center with expertise in gene therapy and stem cell transplantation.

Common side effects include myelosuppression (low blood cell counts), infections, and infusion-related reactions. Patients may experience fatigue, fever, and other symptoms related to the conditioning regimen and immune reconstitution. Serious adverse events such as severe infections and graft complications can occur and require close medical monitoring.

SKYSONA is manufactured by Genetix Biotherapeutics Inc., a biopharmaceutical company specializing in cell and gene therapy development.

Yes, SKYSONA has been granted orphan drug designation by the FDA due to the rarity of cerebral adrenoleukodystrophy and the significant unmet medical need in this patient population. This designation provides regulatory incentives and support for the development and approval of therapies for rare diseases affecting fewer than 200,000 patients in the United States.

Published by GNH India Pharmaceuticals Limited

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing elivaldogene autotemcel